← Back to Clinical Trials
Recruiting NCT06774443

NCT06774443 Hinting Task for Huntington's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06774443
Status Recruiting
Phase
Sponsor University Medical Center Groningen
Condition Huntington Disease
Study Type OBSERVATIONAL
Enrollment 52 participants
Start Date 2025-09-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 74 Years
Study Type OBSERVATIONAL
Interventions
Neuropsychological assessment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 52 participants in total. It began in 2025-09-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by movement disorders, behavioural disorders and cognitive decline. Especially the behavioural and cognitive symptoms of the disease lead to significant disability and burden for patients as well as caregivers. One of the cognitive domains affected by HD is social cognition. Social cognition is the ability to perceive, interpret and respond correctly to social information. Aspects of social cognition are emotion recognition, perspective taking (Theory of Mind), and emapathy. Social cognition problems can be related to behavioural problems, but to be able to study this relationship, it is important to be able to reliable measure social cognition impairments. There are a few social cognition tests available, but often they are not normd and validated for use in a Dutch neurological population. There is a lack of sensitive, simple, tests for measuring Theory of Mind in patients with HD. A promising test, that already has been proven valid in a psychiatric population, is the Hinting Task. The Hinting Task measures theory of mind through indirect speech, The Hinting task is a social cognition test, where hints are implicitly given in speech, which resembles what patients and caregivers frequently report as difficult in HD. The Hinting Task has already been translated into Dutch and is already being used in clinical parctice, but its sensitivity has not been studied yet in a neurological population. The aim of this study is to assess if the Hinting Task is sensitive in patients with HD and to relate the Hinting Task to other (social) cognitive measures, demographical characteristics and disease characteristics.

Eligibility Criteria

Inclusion Criteria: * Confirmed diagnosis of Huntington's disease via CAG-repeat length analysis, minimum of 40 repeats * Between 18 and 74 years of age * Dutch speaking Exclusion Criteria: * Presence of serious psychiatric disorders or other neurological comorbidities

Contact & Investigator

Central Contact

Floor Gelmers

✉ f.gelmers@umcg.nl

📞 +31 50 361 46 64

Principal Investigator

Maraike Coenen

PRINCIPAL INVESTIGATOR

University Medical Center Groningen

Frequently Asked Questions

Who can join the NCT06774443 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 74 Years, studying Huntington Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06774443 currently recruiting?

Yes, NCT06774443 is actively recruiting participants. Contact the research team at f.gelmers@umcg.nl for enrollment information.

Where is the NCT06774443 trial being conducted?

This trial is being conducted at Groningen, Netherlands.

Who is sponsoring the NCT06774443 clinical trial?

NCT06774443 is sponsored by University Medical Center Groningen. The principal investigator is Maraike Coenen at University Medical Center Groningen. The trial plans to enroll 52 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology